[강소기업 줌인] 올해 LO 기대...오버행 리스크 해소｜쓰리빌리언③

Three Billion's 2026 target of securing its first licensing-out deal is crucial for validating whether its AI-powered drug discovery platform and genomic data assets can create independent commercial value. Success would prove the company's expansion from diagnostics into drug discovery represents a sustainable business model rather than a one-off service offering. This achievement will determine whether Three Billion's platform can command valuations as a data-driven pharma partner in the global market.